Goal 2: Reduce Human Disease

Treatment of Major Depression in Patients with Heart Failure

Major depression (MD) is common in patients with heart failure, and it is an independent risk marker for functional decline, hospitalization, and mortality. Two large trials have shown that it can be difficult to treat. SADHART-CHF, a double-blind, placebo-controlled RCT (n=469), found that sertraline was not efficacious for MD in HF. MOOD-HF (n=372) showed that escitalopram was not efficacious. Smaller trials of cognitive-behavioral interventions have produced promising results, but larger trials are needed. Research is also needed on combination therapy (combining behavioral interventions with antidepressants). In short, NHLBI support is needed for Phase II and Phase III trials of treatments for major depression in patients with HF.

Tags (Keywords associated with the idea)


8 net votes
27 up votes
19 down votes
Idea No. 439